title: Constrained corticotropin-releasing factor (CRF) agonists and antagonists with i-(i+3) Glu-Xaa-DXbb-Lys bridges.
abstract: We hypothesized that covalent constraints such as side-chain to side-chain lactam rings would stabilize an alpha-helical conformation shown to be important for the recognition and binding of the human corticotropin-releasing factor (hCRF) C-terminal 33 residues to CRF receptors. These studies led to the discovery of cyclo(20-23)[DPhe12,Glu20,Lys23,Nle21,38]hCRF (12-41) and of astressin ¿cyclo(30-33)[DPhe12,Nle21,38,Glu30,Lys33]hCR F(12-41)¿, two potent CRF antagonists, and of cyclo(30-33)[Ac-Leu8,DPhe12,Nle21, Glu30,Lys33,Nle38]hCRF(8-41), the shortest sequence equipotent to CRF reported to date (Rivier et al. J. Med. Chem. 1998, 41, 2614-2620 and references therein). To test the hypothesis that the Glu20-Lys23 and Glu30-Lys33 lactam rings were favoring an alpha-helical conformation rather than a turn, we introduced a D-amino acid at positions 22, 31, and 32 in the respective rings. Whereas the introduction of a D-residue at position 31 was only marginally deleterious to potency (ca. 2-fold decrease in potency), introduction of a D-residue at position 22 and/or 32 was favorable (up to 2-fold increase in potency) in most of the cyclic hCRF, alpha-helical CRF, urotensin, and urocortin agonists and antagonists that were tested and was also favorable in linear agonists but not in linear antagonists; this suggested a unique and stabilizing role for the lactam ring. Introduction of a [DHis32] (6) or acetylation of the N-terminus (7) of astressin had a minor deleterious or a favorable influence, respectively, on duration of action. In the absence of structural data on these analogues, we conducted molecular modeling on an Ac-Ala13-NH2 scaffold in order to quantify the structural influence of specific L- and DAla6 and L- and DAla7 substitutions in [Glu5,Lys8]Ac-Ala13-NH2 in a standard alpha-helical configuration. Models of the general form [Glu5,LAla6 or DAla6,LAla7 or DAla7,Lys8]Ac-Ala13-NH2 were subjected to high-temperature molecular dynamics followed by annealing dynamics and minimization in a conformational search. A gentle restraint was applied to the 0-4, 1-5, and 8-12 O-H hydrogen bond donor-acceptor pairs to maintain alpha-helical features at the N- and C-termini. From these studies we derived a model in which the helical N- and C-termini of hCRF form a helix-turn-helix motif around a turn centered at residue 31. Such a turn brings Gln26 in close enough proximity to Lys36 to suggest introduction of a bridge between them. We synthesized dicyclo(26-36,30-33)[DPhe12,Nle21,Cys26,Glu30 ,Lys33,Cys36, Nle38]Ac-hCRF(9-41) which showed significant alpha-helical content using circular dichroism (CD) and had low, but measurable potency ¿0. 3% that of 6 or ca. 25% that of [DPhe12,Nle21,38]hCRF(12-41)¿. Since the 26-36 disulfide bridge is incompatible with a continuous alpha-helix, the postulate of a turn starting at residue 31 will need to be further documented.
authors.affiliation: The Clayton Foundation Laboratories for Peptide Biology, The Salk Institute for Biological Studies, 10010 North Torrey Pines Road, La Jolla, California 92037, USA.
authors.forename: S C
authors.initials: SC
authors.lastname: Koerber
authors.forename: J
authors.initials: J
authors.lastname: Gulyas
authors.forename: S L
authors.initials: SL
authors.lastname: Lahrichi
authors.forename: A
authors.initials: A
authors.lastname: Corrigan
authors.forename: A G
authors.initials: AG
authors.lastname: Craig
authors.forename: C
authors.initials: C
authors.lastname: Rivier
authors.forename: W
authors.initials: W
authors.lastname: Vale
authors.forename: J
authors.initials: J
authors.lastname: Rivier
mesh_terms: D000315:Adrenalectomy; D000324:Adrenocorticotropic Hormone / Q000037:antagonists & inhibitors; D000595:Amino Acid Sequence; D000818:Animals; D002478:Cells, Cultured; D002942:Circular Dichroism; D003346:Corticotropin-Releasing Hormone / Q000819:agonists* / Q000037:antagonists & inhibitors* / Q000737:chemistry; D005973:Glutamine / Q000737:chemistry*; D006801:Humans; D008239:Lysine / Q000737:chemistry*; D008297:Male; D008958:Models, Molecular; D008969:Molecular Sequence Data; D010446:Peptide Fragments / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D010456:Peptides, Cyclic / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D010903:Pituitary Gland, Anterior / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D017433:Protein Structure, Secondary; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D010446:Peptide Fragments; D010456:Peptides, Cyclic; D005973:Glutamine; D000324:Adrenocorticotropic Hormone; D003346:Corticotropin-Releasing Hormone; D008239:Lysine